Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation (Nasdaq: GERN) is a commercial-stage biopharmaceutical company focused on blood cancers and myeloid hematologic malignancies through telomerase inhibition. News about Geron frequently centers on its first-in-class telomerase inhibitor RYTELO (imetelstat), which is approved in the United States and the European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) who have transfusion-dependent anemia.
On this page, readers can follow corporate announcements and scientific updates that shape the GERN investment story. Typical news items include financial guidance and quarterly results that discuss RYTELO net product revenue and operating expenses, strategic restructuring plans intended to support the company’s hematology focus, and details of equity grants made under Nasdaq inducement award rules. These disclosures provide insight into Geron’s commercial execution, cost structure and capital allocation.
Geron also issues frequent clinical and medical conference updates. Recent releases have highlighted data presented at the American Society of Hematology (ASH) Annual Meeting, including pooled analyses from the Phase 3 IMerge trial in LR-MDS, long-term outcomes data, and exploratory biomarker studies in myelofibrosis and advanced myelodysplastic neoplasms or acute myeloid leukemia. News about the IMpactMF Phase 3 trial in JAK-inhibitor relapsed/refractory myelofibrosis, as well as the IMbark, IMproveMF and IMpress studies, offers additional context on imetelstat’s development across myeloid malignancies.
Investors can also track leadership changes and investor relations events, such as executive appointments, board updates and participation in healthcare investor conferences. Together, these news items help explain how Geron is pursuing its stated priorities of driving RYTELO commercial growth, expanding access in LR-MDS markets outside the U.S. and advancing its pivotal myelofibrosis program. Bookmark this page to follow ongoing developments affecting GERN’s clinical programs, regulatory milestones, commercial performance and corporate strategy.
Geron Corporation (Nasdaq: GERN) reported strong Q2 2025 financial results, highlighting $49.0 million in RYTELO® net product revenue, representing a 24% increase from Q1. The company announced the appointment of Harout Semerjian as President and CEO and reported significant commercial progress with over 1,000 ordering accounts.
Key financial metrics include a reduced net loss of $16.4 million ($0.02 per share), compared to $67.4 million in Q2 2024. The company maintains a strong cash position of $432.6 million. The Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis has reached 95% enrollment, with full enrollment expected by year-end 2025.
Geron Corporation (Nasdaq: GERN) has appointed Harout Semerjian as its new President and Chief Executive Officer, effective immediately. Semerjian brings over 30 years of commercial experience in hematology and oncology, including significant leadership roles at Novartis, Ipsen, and GlycoMimetics. He succeeds Dawn Carter Bir, who served as Interim President and CEO since March 2025 and will remain on Geron's Board of Directors.
The appointment comes at a crucial time as Geron focuses on expanding the reach of its product RYTELO and advancing its late-stage pipeline, including the IMpactMF Phase 3 trial in relapsed/refractory myelofibrosis. Semerjian's extensive experience includes leading global commercial operations for key hematology therapies like Gleevec® and KISQALI®.
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, has scheduled its second quarter 2025 financial results announcement for August 6, 2025, before market open. The company will host a conference call at 8:00 a.m. Eastern Time to discuss financial results and business highlights.
The announcement will be available through a press release on the company's website, along with a live webcast of the conference call and presentation. The webcast recording will remain accessible on Geron's website for 30 days following the event.
Geron Corporation (Nasdaq: GERN) has granted equity inducement awards to five newly hired employees. The awards, granted on July 17, 2025, include 228,000 stock options with an exercise price of $1.29 per share and 114,000 restricted stock units (RSUs).
The stock options have a ten-year term with a 4-year vesting schedule, starting with 12.5% vesting after six months and the remainder vesting over 42 months. The RSUs vest 25% annually over four years. These awards were granted under Geron's 2018 Inducement Award Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
Geron Corporation (GERN) has granted equity awards totaling 411,000 shares to six new employees as employment inducement. The awards, granted on May 16, 2025, consist of:
- Stock options to purchase 274,000 shares at $1.27 per share (closing price on grant date), with a 10-year term and 4-year vesting schedule
- Restricted Stock Units (RSUs) representing 137,000 shares, vesting 25% annually over 4 years
The grants were approved by Geron's Compensation Committee under Nasdaq Rule 5635(c)(4) and are subject to the company's 2018 Inducement Award Plan terms.
Geron (Nasdaq: GERN) has granted equity awards totaling 1,551,000 shares to twelve new employees as employment inducement. The grants, issued on April 17, 2025, include:
- 1,034,000 shares as stock options with $1.27 per share exercise price
- 517,000 shares as restricted stock units (RSUs)
The stock options have a 10-year term with a vesting schedule of 12.5% after six months and the remaining over 42 months. RSUs vest 25% annually over four years. These awards were approved by Geron's Compensation Committee under Nasdaq Rule 5635(c)(4) and are subject to the company's 2018 Inducement Award Plan.
Geron (GERN) has scheduled the release of its first quarter 2025 financial results before market opening on Wednesday, May 7, 2025. The company will distribute the results via press release, which will be accessible on their investor relations website.
Following the release, Geron will host a conference call at 8:00 a.m. Eastern Time to discuss financial performance and business highlights. Investors can access a live webcast of the conference call and accompanying presentation through the company's website, with the recording remaining available for 30 days afterward.